- Home
- CHY vs PAHC Comparison
CHY vs PAHC Comparison
Compare CHY & PAHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHY | PAHC |
|---|---|---|
| Founded | 2003 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2003 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CHY | PAHC |
|---|---|---|
| Price | $13.74 | $32.16 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $41.25 |
| AVG Volume (30 Days) | 148.4K | ★ 250.7K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 10.11% | 0.91% |
| EPS Growth | N/A | ★ 1883.33 |
| EPS | N/A | ★ 1.90 |
| Revenue | N/A | ★ $833,350,000.00 |
| Revenue This Year | N/A | $17.03 |
| Revenue Next Year | N/A | $3.82 |
| P/E Ratio | ★ N/A | $17.04 |
| Revenue Growth | N/A | ★ 4.12 |
| 52 Week Low | $10.41 | $25.58 |
| 52 Week High | $13.67 | $60.08 |
Technical Indicators
Market Signals| Indicator | CHY | PAHC |
|---|---|---|
| Relative Strength Index (RSI) | 65.20 | 44.94 |
| Support Level | $11.27 | $30.46 |
| Resistance Level | N/A | $34.49 |
| Average True Range (ATR) | 0.21 | 1.22 |
| MACD | 0.01 | 0.46 |
| Stochastic Oscillator | 79.11 | 40.30 |
Price Performance
Historical ComparisonAbout CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.
About PAHC Phibro Animal Health Corporation
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.